NCT06851975

Brief Summary

Research into biomarkers predictive of survival and response to cancer treatment

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40,000

participants targeted

Target at P75+ for not_applicable cancer

Timeline
896mo left

Started Jan 2020

Longer than P75 for not_applicable cancer

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress8%
Jan 2020Dec 2099

Study Start

First participant enrolled

January 7, 2020

Completed
5.1 years until next milestone

First Submitted

Initial submission to the registry

February 14, 2025

Completed
14 days until next milestone

First Posted

Study publicly available on registry

February 28, 2025

Completed
74.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2099

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2099

Last Updated

February 28, 2025

Status Verified

February 1, 2025

Enrollment Period

80 years

First QC Date

February 14, 2025

Last Update Submit

February 24, 2025

Conditions

Cancer

Outcome Measures

Primary Outcomes (1)

  • Prediction

    The aim of this project is to make a biobank in prevision of MR004 sub-projects which define specific biomarkers studied to identify biomarkers predictive of response.

    day 1

Study Arms (1)

principal

OTHER

blood sampling

Other: blood sampling

Interventions

blood samplingOTHER

36ml of blood will be taken during a blood sampling performed in standard practice

principal

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient having a blood test, venous line insertion or injection on an implantable venous device scheduled as part of their standard care,
  • Patient who has read the information note and stated that he/she has no objections
  • Patient who has not objected to the use of this data for medical research purposes
  • Patient with social security cover.

You may not qualify if:

  • Patient already included in the study
  • Patient considered to be a vulnerable person; vulnerable persons are defined in article L1121-5 to -8

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre Antoine Lacassagne

Nice, 0600, France

RECRUITING

MeSH Terms

Conditions

Neoplasms

Interventions

Blood Specimen Collection

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative Techniques

Central Study Contacts

Victoria FERRARI, Dr

CONTACT

+33 492031311victoria.ferrari@nice.unicancer.fr

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 14, 2025

First Posted

February 28, 2025

Study Start

January 7, 2020

Primary Completion (Estimated)

December 31, 2099

Study Completion (Estimated)

December 31, 2099

Last Updated

February 28, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will share

pseudonymised data will only be collected

Shared Documents
STUDY PROTOCOL, CSR
Time Frame
at the end of study

Locations

FR(1)